Stay updated with breaking news from Dermatol venerol. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis - Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1) - The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials(1) - Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 children worldwide, with onset most common during adolescence(2,3) News provided by Share this article Share this article EAST HANOVER, N.J., June 1, 2021 /PRNewswire/ Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx ....
NOVARTIS AG CHF0.50(REGD) Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials and is consistent with the established adult psoriasis indication 1 Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 children worldwide, with onset most common during adolescence ....
Novartis Pharma AG: Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis Cosentyx demonstrated superior improvements of skin symptoms compared to placebo 1 The safety profile of Cosentyx in pediatric patients with plaque psoriasis was demonstrated in two Phase III trials and is consistent with the established adult psoriasis indication 1 Plaque psoriasis is a chronic, inflammatory disease that may impact up to 350,000 children worldwide, with onset most common during adolescence 2,3 Basel, June 1, 2021 - Novartis, a leader in immuno-dermatology and rheumatology, today announced the U.S. Food and Drug Administration (FDA) has approved Cosentyx ....